Pancreatic Stone Protein in patients with liver failure: A prospective pilot cohort study
Authors' conclusion
This pilot study provides early insights into PSP kinetics, suggesting a potential role for prognosis in patients with LF. PSP rises in both ALF and ACLF to levels sustainably higher than those expected for healthy adults.
Study context
- Population
- Patients with liver failure (acute or acute-on-chronic) consecutively admitted to the ICU of a liver transplant center in 2021–2023, without ongoing overt infection7 acute, 9 acute-on-chronic liver failure (LF)
- Participants
- 16 patients
- Exposure
- Pancreatic Stone Protein (PSP) levels in infected vs non-infected, non-survivors vs survivors
- Infectedn = 8
- Outcome
- Accuracy of PSP for diagnosis of infection and prognosis
Methodological detailspilot, single-centre
- Pilot
- Single-centre
Main finding
As reported in the abstract
PSP levels, infected vs non-infected · during follow-up
- Non-significantly higher PSP in infected than non-infected patients
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| PSP levels, non-survivors vs survivors · from D4 on | P < 0.05 |
| PSP levels, RRT vs no RRT · D2 to D7 after admissionHigher with RRT | P < 0.05 |
- PSP levels, non-survivors vs survivors: higher in non-survivors; also since day of infection in infected patients
Hospital mortality
- Hospital mortality
- 43.8% (n = 7)
Original publication
Pancreatic Stone Protein in patients with liver failure: A prospective pilot cohort study. Anaesth Crit Care Pain Med. Published 30 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →